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To the Editor: Varied dosing regimens of rituximab
(RTX) have been successfully used in the management
of primary membranous nephropathy (PMN).1,2 An
ideal RTX dose and the long-term adverse effect of a
larger cumulative dose are not clear. CD19 levels are
used to gauge the drug effect.1 Economic viability is a
major part of any new therapeutic regimen. Low-dose
RTX (100 mg) has been successfully used in ABO
incompatible renal transplant.3 In the present study,
we report a similar approach of CD19 depletion using
100 mg of RTX in the management of M-type
phospholipase A2 receptor antibody (aPLA2R)-
associated PMN refractory, dependent on or intol-
erant to conventional immunosuppressive regimens
recommended by Kidney Disease: Improving Global
Outcomes.4
All the study subjects had aPLA2R-related PMN. The
mean duration of nephrotic syndrome before RTX
therapy was 33.67  19.76 (median 13, range 10–62)
months. Before receiving RTX, all the patients had an
immunosuppression-free washout period of minimum 3
months. The mean proteinuria, serum albumin, and
creatinine were 12.06  10.78 (median 7.59, range
2.30–31.00) g/d, 2.09  0.95 (median 1.64, range
1.30–3.50) g/dl, and 0.81  0.21 (median 0.80,
range 0.60–1.10) mg/dl, respectively. Five (83.3%)
study subjects had nephrotic range proteinuria (>4 g/d)
and 1 (16.7%) patient had subnephrotic proteinuria
(2.3 g/d) and was treated as he had anasarca with severe
hypoalbuminemia (1.3 g/dl) and hypercholesteremia.
All the study subjects (4 resistant to cyclophosphamide
and steroids, 1 intolerant to tacrolimus treatment, and 1
with relapsing disease) were treated with 100 mg of
rituximab (CD19 monitored on day 2 and at every 4- to
6-week interval). In subjects with no response at
6 months, further infusion and monitoring was stopped
(extended follow-up continued). All the subjects
achieved CD19 depletion (<1%) with a single dose ofKidney International Reports (2017) 2, 89–93100 mg of RTX. All the patients received maximal toler-
able doses of angiotensin receptor blockers (systolic blood
pressure achieved was <130 mm Hg in all the subjects)
and atorvastatin; doses of angiotensin receptor blockers
were stable during the entire study period. During RTX
therapy, the patients received no other immunosup-
pressive therapy. At the end of 6 months, 3 (50%) ach-
ieved remission in proteinuria with normalization of
serum albumin, and had maintained it until the last
follow-up (Table 1). All the subjects in clinical remission
also had serological remission and nonresponders had
persisting aPLA2R (Table 1). The mean time for CD19
reconstitution was 2.17  1.17 (median 2, range 1–4)
months. A total of 16 additional doses of RTX were
required (mean 2.67  0.82, median 2.5, and range 2–4).
Low-dose RTX has been successfully used in ABO
incompatible renal transplant. Nakao et al.3 reported
successful use of 100 mg of RTX in 9 ABO incompatible
renal transplant, with no difference in survival rates
between low versus standard dose. Low dose of RTX has
also been successfully evaluated in refractory rheuma-
toid arthritis.5 Shenoy et al.5 evaluated the therapeutic
response of 100 mg of RTX in 14 patients with active
rheumatoid arthritis; 58% and 42% of the patients
achieved good and moderate response at 24 weeks,
respectively. Seventy-nine percent of the patients ach-
ieved CD19 depletion (<0.01%) with single dose of RTX
(100 mg). The CD19 depletion in the present study is
better than that reported by Shenoy et al.; this may
partly be explained by the difference in the deﬁnition of
CD19 depletion (<1% and <5 cells in the present study
vs. <0.01% in the study by Shenoy et al.).5
Ruggenenti et al.1 studied RTX use in 100 subjects
with PMN and reported a response rate of 56% (18 of 32
cases), when used as a second line agent. In the present
study, the response rate of 50% was similar to that re-
ported by Ruggenenti et al.1 Ruggenenti et al. used a
single dose of 375 mg/m2 in all the patients compared
with 100 mg with CD19 monitoring in the present
study. Treatment protocol utilizing RTX in PMNwidely
varies among various centers; some prefer to use
“extended protocol” of weekly (375 mg/m2) RTX for 4
weeks,6 whereas others choose to use CD19 targeted
RTX infusion. Interestingly, most of the studies have
demonstrated successful depletion of CD19 with a single
dose, questioning the beneﬁt of additional dosing, and
many centers have evolved from “extended protocol” to
“CD19 targeted dosing.”1,6 Assuming that CD19 deple-
tion primarily translates to clinical response, any dose
that achieves it must be acceptable. aPLA2R has very
good association with clinical activity;7 in the present
report, all the responders had reduction in aPLA2R89
Table 1. Clinical and biochemical parameters of all the 6 subjects
S No.
Primary
IST Indication
Baseline
Second month
completion
Fourth month
completion
Sixth month
completion
F/U
(mo)
Last follow-up aPLA2R (RU/ml) RTX
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl) Pre-RTX Post-RTX
Additional
doses
Time
(mo)
1 cCTX/GC Relapse 8.98 3.10 3.88 3.10 3.60 3.20 1.03 3.60 14 0.701 3.70 73.11 4.528 02 03, 08
2 cCTX/GC Resistant 6.20 1.40 1.20 5.50 1.25 5.20 3.00 2.10 12 3.20 3.10 121.59 93.99 03 01, 04, 05
3 TAC Intolerant 2.30 1.30 2.90 3.13 2.86 3.42 1.92 4.32 15 0.29 4.32 28.87 2.00 04 04, 09, 12, 15
4 cCTX/GC Resistant 5.50 3.50 2.90 3.90 3.10 3.20 3.20 4.40 13 1.13 4.34 111.87 2.00 02 02, 06
5 cCTX/GC Resistant 31.00 1.68 16.220 1.59 3.80 1.98 19.60 1.83 10 8.80 3.50 27.13 79.76 02 01, 04
6 cCTX/GCa Resistant 18.41 1.60 15.03 1.30 9.58 2.63 8.00 2.00 14 3.13 3.30 59.89 56.79 03 02, 05, 06
Mean time to CD19 repletion was 2.17  1.17 (range 1–4) mo and all the subjects received further therapy (median doses 2.5, range 2–4).
aPLA2R, m-type phospholipase A2 receptor antibody; cCTX/GC, cyclical cyclophosphamide and steroids; F/U, follow-up; IST, immunosuppressive therapy; RTX, rituximab; Sr Alb, serum
albumin; TAC, tacrolimus; UP, urine protein.
aPatient developed upper respiratory tract infection, which was successfully managed with oral antibiotics.
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RESEARCH LETTERSto <20 RU/ml, whereas none of the nonresponders
achieved similar titer. Our results support the incor-
poration of aPLA2R monitoring in the management of
difﬁcult to treat PMN.
To conclude, in cost-restrained setting, low-dose
RTX targeting CD19 depletion can be used in the
management of PMN refractory to standard immuno-
suppressive therapies with the acceptable side effect
proﬁle.
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Albumin Correlate With
Dietary Protein Intake in
Dialysis Patients?
To the Editor: Serum albumin is a useful screening
tool for recognizing protein energy wasting (PEW) in
dialysis patients. However, there are many nonnutri-
tional conditions that are far more important de-
terminants of serum albumin levels than a patient’s
nutritional state.1,2 Nevertheless, we have observed
that it is not unusual for caregivers to make a reﬂex
connection between serum albumin and dietary protein
intake and to act on an unfounded belief that proteinKidney International Reports (2017) 2, 89–93
